Search

Displaying results 1461 - 1470 of 10000 in total
  1. Drug

    Ergoloid mesylate

    go.drugbank.com/drugs/DB01049
    Approved

    Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. … Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.

  3. Drug

    Sulfamethoxazole

    go.drugbank.com/drugs/DB01015
    ApprovedInvestigational

    Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. … [L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.

    Mixtures: MAXTRIM-P, COTRIMOXAZOL ALCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and T lymphocytes. … [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell

    Categories: P-glycoprotein substrates
  5. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.

    Products: TRUXİMA 500 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, MABTHERA 100 MG/10 ML IV INFUZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 2 ADET
  6. Drug

    Albendazole

    go.drugbank.com/drugs/DB00518
    ApprovedInvestigationalVet approved

    A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)

    Mixtures: AH MICOL, AH-MICOLCategories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  7. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. … Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469].

    Products: REMİCADE 100 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ (1 ADET), REMICADE 100 MG KONSANTRE IV INFUZYON COZELTISI HAZIRLAMAK ICIN LIYOFILIZE TOZ ICEREN FLAKON, 1 ADET
  8. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener. … [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.

  9. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. … Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  10. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl … Elapegademase is a PEGylated recombinant adenosine deaminase.

    Synonyms: AN AVERAGE OFAPPROXIMATELY 13 .OMEGA., (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED